Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7810.006 | uM | inf | inf | 0.8576 | 0.8576 | 0.0000 | 0.0064 | 0.5591 | 0.9730 | |
HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7811.018 | uM | inf | inf | 0.6946 | 0.6946 | 0.0000 | 0.1308 | -0.0060 | 0.4694 | |
HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7812.042 | uM | inf | inf | 0.5614 | 0.5614 | 0.0000 | 0.0267 | 0.3674 | 0.9722 | |
HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9258.026 | uM | inf | inf | 0.7953 | 0.7953 | 0.0000 | 0.0354 | 0.3593 | 0.5632 | |
HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7813.018 | uM | 0.82620 | 0.82952 | 0.7195 | -0.0101 | 4.9982 | 0.0073 | 0.6447 | 0.8420 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9146.122 | uM | inf | inf | 0.9694 | 0.9694 | 0.0000 | -0.0404 | -1.9847 | 1.3408 | |
184B5 | NM | Basal | Cetuximab | EGFR | ErbB | 9095.026 | uM | 0.04089 | 0.03186 | 0.1205 | 0.1008 | 0.9024 | 0.1873 | 0.9743 | 1.0168 | |
184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 7787.018 | uM | inf | inf | 0.4652 | 0.4652 | 0.0000 | 0.3838 | -0.0013 | 0.3791 | |
600MPE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9118.006 | uM | inf | inf | 0.8545 | 0.8545 | 0.0000 | 0.0747 | 0.3005 | 1.1089 | |
184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 9047.026 | uM | 0.00360 | 0.01403 | -0.2605 | -0.4617 | 0.4805 | 0.4918 | 0.8777 | 0.5972 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7793.018 | uM | inf | inf | 0.9318 | 0.9318 | 0.0000 | 0.0067 | 0.3477 | 1.3186 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7794.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.6812 | |
BT-20 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 5903.102 | uM | inf | 0.01035 | 0.7898 | 0.7837 | 0.8245 | 0.0669 | 0.9137 | 1.2557 | |
BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7798.018 | uM | inf | inf | 1.0028 | 1.0028 | 0.0000 | -0.0260 | -0.7402 | 1.4461 | |
BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9158.123 | uM | inf | inf | 0.7610 | 0.7610 | 0.0000 | 0.0813 | 0.5069 | 0.8769 | |
BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7801.018 | uM | inf | inf | 0.7533 | 0.7533 | 0.0000 | 0.1055 | 0.0672 | 0.5913 | |
BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9186.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5108 | |
BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7804.042 | uM | inf | 1.1360 | 0.9560 | 0.7915 | 2.6263 | -0.0076 | 0.5868 | 2.4955 | |
BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 10261.026 | uM | inf | inf | 0.9943 | 0.9943 | 0.0000 | -0.0202 | -1.1867 | 2.4866 | |
BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9024.018 | uM | inf | 0.02553 | 0.8627 | 0.8547 | 0.7831 | 0.0371 | 0.8155 | 2.8306 | |
BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7803.042 | uM | 1.64710 | 3.27740 | 0.7927 | -0.6886 | 1.2586 | 0.0007 | 0.8536 | 2.8270 | |
HBL-100 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7807.042 | uM | inf | inf | 1.0098 | 1.0098 | 0.0000 | -0.0392 | -7.7987 | 2.0250 | |
HBL-100 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7808.052 | uM | inf | inf | 0.9944 | 0.9944 | 0.0000 | -0.0231 | -0.8225 | 2.4842 | |
HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7834.018 | uM | inf | inf | 0.8939 | 0.8939 | 0.0000 | 0.0410 | 0.4149 | 1.8951 | |
HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7833.042 | uM | inf | inf | 0.8856 | 0.8856 | 0.0000 | 0.0972 | 0.0274 | 1.0332 |